CRISPR Therapeutics director Ali Behbahani disposes of common shares worth $780,649.24
CRSP•Director exercises options and sells shares
- CRISPR Therapeutics director Ali Behbahani exercised stock options for 30,000 common shares at USD 14 on Sept. 17, 2026.
- Behbahani sold 13,679 common shares at USD 57.09 on the same day.
- Directly held common shares totaled 16,637 following the transactions.
